Journal of the American Chemical Society · 2020 · 110 citations · 23 references
PharmacyMedicinal ChemistryMolecular BiologyDrug DesignDrug DiscoveryMolecular OncologyCovalent Inhibitor DesignEnzyme InhibitionLigand BindingMolecular DockingProtein-ligand DockingVirtual Screening5' Cap StructureCovalent DockingDocking-based Drug DesignLysine-targeted Covalent DrugsLysine-targeted InhibitorsMolecular Docking Of InhibitorsSmall-molecule DockingTargeted Covalent Inhibitors
Eukaryotic translation initiation factor 4E (eIF4E) binds the m7GTP cap structure at the 5′-end of mRNAs, stimulating the translation of proteins implicated in cancer cell growth and metastasis. eIF4E is a notoriously challenging target, and most of the reported inhibitors are negatively charged guanine analogues with negligible cell permeability. To overcome these challenges, we envisioned a covalent targeting strategy. As there are no cysteines near the eIF4E cap binding site, we developed a covalent docking approach focused on lysine. Taking advantage of a “make-on-demand” virtual library, we used covalent docking to identify arylsulfonyl fluorides that target a noncatalytic lysine (Lys162) in eIF4E. Guided by cocrystal structures, we elaborated arylsulfonyl fluoride 2 to 12, which to our knowledge is the first covalent eIF4E inhibitor with cellular activity. In addition to providing a new tool for acutely inactivating eIF4E in cells, our computational approach may offer a general strategy for developing selective lysine-targeted covalent ligands.
23
Ultra-large library docking for discovering new chemotypes
Jiankun Lyu, Sheng Wang, Trent E. Balius et al. · Nature · 2019 · 988 citations
Differential Requirements for eIF4E Dose in Normal Development and Cancer
Morgan Truitt, Crystal S. Conn, Zhen Shi et al. · Cell · 2015 · 396 citations · Full text